Jump to content

Mesothelioma Prognosis

From WikiMesothelioma — Mesothelioma Knowledge Base
Mesothelioma Prognosis
Individual Prognostic Factors & Scoring Systems
Median OS (Treated) 12–21 months
BAP1 Carrier Median OS 5 years
Best Scoring System PLECH (AUC 0.70)
Under-50 5-Year Survival 39.2%
Female 5-Year Survival 13.4% vs. 4.5% male
Key Prognostic Factors Stage, histology, PS, age, BAP1, NLR
Free Case Review →

Mesothelioma Prognosis

Overview

Mesothelioma prognosis describes the likely course and outcome of the disease for an individual patient, as distinct from population-level survival statistics.[1] While overall median survival for treated pleural mesothelioma ranges from 12 to 21 months, individual prognosis varies dramatically based on measurable factors including disease stage, histologic subtype, performance status, age, gender, blood biomarkers, and molecular characteristics such as germline BAP1 mutations.[2][3] Multiple validated prognostic scoring systems — including EORTC, CALGB, Brims, and the 2025 PLECH score — combine these variables to stratify patients into risk groups with significantly different survival expectations.[4][5] Understanding individual prognostic factors helps patients make informed treatment decisions and empowers families to pursue appropriate legal compensation within applicable deadlines.[6]

Mesothelioma prognosis at a glance:

  • Treated patients survive 12–21 months on average — but individual outcomes vary dramatically based on stage, histology, age, gender, and molecular markers
  • BAP1 mutation carriers survive 7 times longer — median 5 years compared to less than 1 year for non-carriers, making genetic testing critical
  • Epithelioid subtype doubles survival — 14–18 months median versus 4–8 months for sarcomatoid, with 5-year rates of 14% versus 4%
  • Women survive nearly 3 times longer — 13.4% five-year survival versus 4.5% for men, with 22% reduced mortality risk (HR 0.78)
  • Age under 50 means 39% five-year survival — compared to just 4.5% for patients 75 and older, a nearly 9-fold difference
  • PLECH score (2025) predicts survival most accurately — AUC 0.70 outperforms CALGB (0.60) and EORTC (0.57) scoring systems
  • Elevated NLR signals significantly higher mortality — one-year survival drops substantially when this simple blood test ratio is high
  • Peritoneal patients with complete surgery survive 8.7 years — median 104 months after cytoreductive surgery with HIPEC
  • High-volume centers reduce surgical death by 31% — 10.0% versus 14.6% ninety-day mortality at specialized facilities

Key Facts

Key Facts: Mesothelioma Prognosis
  • Median Overall Survival: 12–21 months with active treatment; 7–8 months in population-based registries including untreated patients[2]
  • BAP1 Mutation Carriers: 7-fold improved long-term survival with median of 5 years versus less than 1 year for non-carriers[3]
  • Epithelioid vs. Sarcomatoid: 14–18 months vs. 4–8 months median survival; epithelioid 5-year survival approximately 14% vs. 4% for sarcomatoid[7][8]
  • Gender Difference: Women show HR 0.78 (22% reduced mortality risk) with 5-year survival of 13.4% vs. 4.5% for men[9]
  • Age Effect: Under 50: 39.2% five-year survival; 75+: 4.5% five-year survival — nearly 9-fold difference[10]
  • PLECH Score (2025): AUC 0.70 for 1-year overall survival prediction, outperforming CALGB (0.60) and EORTC (0.57)[4]
  • NLR Biomarker: Elevated neutrophil-to-lymphocyte ratio is associated with significantly reduced survival[11]
  • Peritoneal with CC-0: Complete cytoreduction achieves median 104 months (8.7 years) survival[12]
  • Performance Status: Independent predictor in every validated scoring system; ECOG 0–1 required for most curative-intent treatments[5][13]
  • Specialized Centers: High-volume facilities show lower 90-day mortality (10.0% vs. 14.6%, p=0.029) after mesothelioma surgery[14]

What Factors Determine Mesothelioma Prognosis?

Mesothelioma prognosis is shaped by a combination of disease-related, patient-related, and treatment-related factors.[15] Unlike many cancers where staging alone drives prognosis, mesothelioma outcomes depend on a broader constellation of variables that clinicians assess collectively.

Disease-Related Factors include the anatomic site (pleural, peritoneal, pericardial, or testicular), histologic subtype (epithelioid, sarcomatoid, or biphasic), disease stage at diagnosis, and molecular characteristics such as BAP1 mutation status.[16][17] Peritoneal mesothelioma carries a fundamentally different prognosis than pleural disease, particularly when treated with cytoreductive surgery and HIPEC.[18]

Patient-Related Factors encompass performance status (ECOG score), age at diagnosis, gender, nutritional status (serum albumin), and laboratory values including hemoglobin, white blood cell count, platelet count, lactate dehydrogenase (LDH), and the neutrophil-to-lymphocyte ratio (NLR).[4][13] These measurable values form the basis of validated prognostic scoring systems.

Treatment-Related Factors include whether multimodal therapy is pursued, the completeness of surgical resection, access to immunotherapy, enrollment in clinical trials, and treatment at a high-volume specialized center.[19][20] Patients who receive treatment at NCI-designated cancer centers with dedicated mesothelioma programs consistently achieve better outcomes.[21]

ℹ Note: Prognosis is a statistical estimate based on groups of patients with similar characteristics — it does not predict what will happen to any individual. Some patients significantly outlive their predicted prognosis, particularly those with favorable molecular profiles such as BAP1 mutations.

How Do Prognostic Scoring Systems Predict Outcomes?

Four validated prognostic scoring systems have been developed specifically for mesothelioma, each combining multiple clinical variables to stratify patients into risk groups.[4][5] These tools help oncologists set treatment expectations and guide decision-making about aggressive versus palliative approaches.

EORTC Prognostic Score (1998)

The European Organisation for Research and Treatment of Cancer score was the first validated mesothelioma prognostic model, developed from 204 patients across 5 phase II trials between 1984 and 1993.[5]

Variables: Poor performance status, high white blood cell count, probable or possible histologic diagnosis, male gender, and sarcomatous histology.[5]

Prognostic Group Criteria 1-Year Survival
Good prognosis 2 or fewer of the 5 factors 40% (95% CI: 30–50%)
Poor prognosis 3 or more of the 5 factors 12% (95% CI: 4–20%)

The EORTC score was externally validated at St. Bartholomew's Hospital (n=145), showing median survival of 19.2 months for the good-prognosis group versus 9.9 months for poor-prognosis. However, in contemporary analyses, its discriminatory power is limited (AUC 0.57).[22][4]

CALGB Prognostic Score (1998)

The Cancer and Leukemia Group B score was developed from 337 patients across 7 phase II clinical trials, using regression tree analysis to identify 6 prognostic groups based on performance status, age, chest pain, dyspnea, platelet count, weight loss, LDH, hemoglobin, white blood cell count, and histologic subtype.[22][23]

The CALGB score was validated in a Leicester series (n=142) with results equivalent to the original data. Current AUC for 1-year overall survival prediction: 0.60.[4]

Brims Decision Tree Model (2016)

Developed from 482 cases with 174-case external validation (2005–2014), the Brims model uses a decision tree approach with five variables: weight loss, hemoglobin, serum albumin, performance status, and histology.[13][24]

Risk Group 18-Month Survival Median Survival Characteristics
Group 1 (best) 86.7% 34.0 months No weight loss, Hb >153 g/L, albumin >43 g/L
Group 2 Intermediate Intermediate No weight loss, not meeting Group 1 lab criteria
Group 3 Intermediate Intermediate Weight loss present, PS 0–1, epithelioid histology
Group 4 (worst) 0% 7.5 months Weight loss present, PS 0–1, sarcomatoid histology

The Brims model achieved a C-statistic of 0.761 (derivation) and 0.68 (validation) with 94.5% sensitivity. The British Thoracic Society endorses it as a clinical tool to consider at diagnosis.[24][13]

PLECH Score (2025)

The newest and most accurate prognostic model, PLECH was developed from 262 patients at two cancer centers (2010–2023). Its name reflects the five weighted variables:[4]

  • Platelet count (high): +2 points
  • LDH (high): +1 point
  • ECOG ≥2: +1 point
  • Chest pain at diagnosis: +2 points
  • Non-epithelioid Histology: +1 point

Score range: 0–7 points. Optimal cut-off: 2.5.[4]

Risk Group Median OS Median PFS
Low risk (score <3) 20.1 months 11.3 months
High risk (score ≥3) 12.3 months 6.4 months

The PLECH score achieved an AUC of 0.70 for 1-year overall survival prediction, outperforming both CALGB (0.60) and EORTC (0.57) in the same patient population.[4]

"We advocate for early case evaluation because prognostic data directly informs legal strategy. A patient's scoring system results and biomarker profile shape not only treatment planning but also the urgency of filing claims before applicable deadlines expire."
— Paul Danziger, Founding Partner, Danziger & De Llano

How Does ECOG Performance Status Predict Outcomes?

The Eastern Cooperative Oncology Group (ECOG) Performance Status scale — a 0-to-5 clinician-rated measure of functional capacity — is among the strongest independent prognostic factors in mesothelioma and the gating eligibility criterion for nearly every disease-modifying treatment. ECOG 0 (fully active) and ECOG 1 (restricted in strenuous activity but ambulatory) define the population eligible for aggressive multimodal therapy, immunotherapy, and clinical trials. ECOG 2 patients face a clinical "gray zone" where toxicity risk rises sharply but selected therapies remain available. ECOG ≥3 generally contraindicates systemic therapy in favor of palliative care.[25]

A retrospective analysis of malignant peritoneal mesothelioma patients treated with cytoreductive surgery confirmed ECOG score as an independent prognostic factor in multivariate Cox regression (odds ratio 3.91, 95% CI 1.035–3.572; p=0.017), with ECOG <3 patients achieving 77.27% survival versus 40.91% for ECOG ≥3 patients on univariate analysis (p=0.014).[25] The pattern aligns with broader oncology evidence demonstrating that immunotherapy and aggressive systemic therapy benefit drops sharply for patients with ECOG PS ≥2 across solid tumor types.

The pivotal CheckMate 743 trial, which established nivolumab plus ipilimumab as the first new FDA-approved first-line regimen for unresectable pleural mesothelioma in over 15 years, restricted enrollment to patients with ECOG PS 0 or 1: 38% of the immunotherapy arm had PS 0 and 62% had PS 1.[26] The trial reported median overall survival of 18.1 months with nivolumab plus ipilimumab versus 14.1 months with platinum-pemetrexed chemotherapy in the overall population, with the histology-stratified analysis showing the largest absolute benefit in non-epithelioid disease (16.9 months vs. 8.8 months).[26] Five-year follow-up data published in 2026 confirmed durable survival benefit, with 14% of patients alive at five years on the immunotherapy combination versus 6% on chemotherapy.[27]

Performance status is also embedded in every validated mesothelioma prognostic scoring system. The PLECH score assigns a +1 point penalty for ECOG ≥2; the EORTC and CALGB scores both include performance status as a core variable; and Danish clinical guidelines published in 2025 explicitly limit surgical eligibility to patients with ECOG PS 0–1, age below 75, preserved cardiac and pulmonary function, Stage I–IIIA disease, and epithelioid or low-sarcomatoid biphasic histology.[28][4]

What Role Do Blood Markers Play in Prognosis?

Several routine laboratory values serve as independent prognostic indicators in mesothelioma, many of which are incorporated into the scoring systems described above.[4][13]

Biomarker Direction Impact Evidence
Neutrophil-to-Lymphocyte Ratio (NLR) Elevated NLR = worse Elevated HR; significantly reduced 1-year survival Meta-analysis[11]
Platelet Count High = worse +2 points in PLECH score (highest weight) PLECH 2025[4]
LDH (Lactate Dehydrogenase) High = worse Independent predictor; +1 in PLECH PLECH 2025, CALGB[4][22]
Hemoglobin Normal/high = better Hb >153 g/L associated with Group 1 (best) prognosis Brims 2016, EORTC[13][5]
Serum Albumin High = better Albumin >43 g/L associated with best prognostic group Brims 2016[13]
White Blood Cell Count High = worse Leukocytosis independently predicts poor outcome EORTC, SEER[5][2]

These biomarkers are particularly valuable because they are measured through routine blood tests available at any medical facility and can be monitored throughout treatment to track disease trajectory.[29]

How Do BAP1 Mutations Affect Long-Term Survival?

Germline BAP1 (BRCA1-associated protein 1) mutations represent the most significant molecular prognostic factor identified in mesothelioma, conferring dramatically improved long-term survival.[3][30]

In a landmark study comparing 23 mesothelioma patients with germline BAP1 mutations to 10,556 SEER controls:[3]

  • Actuarial median survival: 5 years (versus less than 1 year for SEER controls)
  • 5-year survival: 47% (95% CI: 24–67%) versus 6.7% (6.2–7.3%) in SEER
  • 7-fold improved long-term survival, independent of sex and age
  • Peritoneal BAP1 carriers: Median survival of 10 years
  • Carriers with second malignancy: Median survival of 10 years

BAP1 carriers tend to develop epithelioid histology, respond exceptionally well to platinum-based chemotherapy, and demonstrate significantly enhanced chemosensitivity compared to sporadic mesothelioma cases.[31][32]

✓ BAP1 Tumor Predisposition Syndrome: BAP1-TPDS (OMIM #614327) is an autosomal dominant hereditary cancer syndrome. Clinical practice guidelines (2023) recommend genetic counseling and surveillance for carriers, including regular imaging for mesothelioma detection. Given the improved survival in BAP1-associated mesothelioma, surveillance may allow earlier intervention and better outcomes.[33]

A 2022 review by leading researchers noted that a fraction of BAP1 carrier patients "actually live 10 to 20 years and probably will not die of mesothelioma."[32] This represents a fundamentally different disease biology with implications for treatment intensity, surveillance strategy, and long-term planning.

What Factors Can Improve a Patient's Prognosis?

While mesothelioma prognosis depends partly on immutable factors like age and gender, several modifiable factors can meaningfully influence outcomes:[20][23]

Early-Stage Diagnosis: Stage I patients have 5-year survival of 33% versus 4% for Stage IV. Localized disease at SEER summary staging achieves 23% five-year relative survival.[34][17]

Treatment at a Specialized Center: A National Cancer Database analysis (n=1,307) demonstrated that high-volume facilities achieve lower 30-day readmission rates (4.6% vs. 6.1%, p=0.021) and lower 90-day mortality (10.0% vs. 14.6%, p=0.029) compared to lower-volume centers.[14][21]

Multimodal Treatment: Patients receiving surgery achieve median overall survival of 15 months versus 8 months without surgery (SEER data). The combination of chemotherapy, surgery, and repeat chemotherapy has achieved 3-year survival rates of 65% in selected patient populations.[35][15]

Immunotherapy Access: The CheckMate 743 trial demonstrated that nivolumab plus ipilimumab achieves median overall survival of 18.1 months versus 14.1 months with chemotherapy alone, with 28% of responders maintaining response at 3 years compared to 0% with chemotherapy.[36][37]

Clinical Trial Enrollment: Trial participants often receive cutting-edge treatments with rigorous monitoring. Both CheckMate 743 and the STELLAR trial (TTFields) demonstrated meaningful survival improvements over standard care.[38][39]

Maintaining Performance Status: Good physical fitness (ECOG 0–1) is a prerequisite for most curative-intent therapies and is an independent predictor of survival across all validated scoring systems.[5][13][4]

Who Are Long-Term Mesothelioma Survivors?

Long-term survival in mesothelioma is generally defined as surviving 5 or more years after diagnosis. At the population level, approximately 12–15% of pleural mesothelioma patients and up to 65% of peritoneal mesothelioma patients reach this milestone.[29][40]

Characteristics of Long-Term Survivors

Analysis of published case series and National Cancer Database data reveals consistent patterns among mesothelioma long-term survivors:[40][10]

  • Younger age: Under 50: 5-year survival 39.2%, 10-year survival 33.4%[10]
  • Female gender: Independent predictor of improved survival (HR 0.78)[9]
  • Epithelioid histology: Predominates among long-term survivors[2]
  • Multimodal therapy: Surgery plus chemotherapy plus/minus radiation is the most common treatment among survivors[30]
  • Complete cytoreduction: CC-0 resection critical, particularly for peritoneal disease — median survival 104 months with CC-0 versus 30 months with CC-1[12]
  • Good performance status: ECOG 0–1 at diagnosis[13]
  • BAP1 germline mutation carriers: 47% five-year survival with molecularly favorable disease biology[3]

In a NCDB analysis of 3,636 peritoneal mesothelioma patients, 17.8% (n=648) qualified as long-term survivors with a median survival of approximately 92 months.[40] For peritoneal disease specifically, surgery plus HIPEC achieved the longest median overall survival (65.9 months) compared to surgery plus systemic therapy (38 months) or surgery alone (9.6 months).[40]

How Does Age Affect Mesothelioma Prognosis?

Age at diagnosis is a continuous independent predictor of mesothelioma survival, with younger patients demonstrating dramatically better outcomes across all types and stages.[10][2]

Age at Diagnosis 1-Year Survival 3-Year Survival 5-Year Survival 10-Year Survival
Under 50 68.6% 47.1% 39.2% 33.4%
50–64 54.9% 23.7% 15.3% 8.1%
65–74 38.1% 11.8% 6.4% 2.7%
75+ 33.0% 9.3% 4.5% 1.7%

Source: NCI SEER database[10]

Patients under 50 have nearly 9-fold better 5-year survival (39.2%) compared to those 75 and older (4.5%). This disparity reflects both disease biology — younger patients more frequently have BAP1-associated disease and peritoneal location — and the ability to tolerate aggressive multimodal treatment including surgery.[41][42]

Young-onset mesothelioma (under 40) is more likely to be associated with germline BAP1 mutations, peritoneal rather than pleural location (especially in young women), or exposure to alternative mineral fibers such as erionite.[41][33]

⚠ Important: Regardless of prognosis, statutes of limitations for mesothelioma lawsuits typically range from 1 to 6 years from diagnosis and do not pause based on treatment outcomes. Even patients with favorable prognostic profiles should consult with experienced mesothelioma attorneys promptly to preserve all legal options.[43][44]

Frequently Asked Questions

What is the average prognosis for mesothelioma?

The average mesothelioma prognosis depends heavily on disease type, stage, and treatment. For pleural mesothelioma with active treatment, median overall survival is 12 to 21 months. Peritoneal mesothelioma treated with CRS/HIPEC can achieve median survival exceeding 50 months. Individual prognosis may differ significantly from averages based on the prognostic factors described on this page.[1][12]

Can mesothelioma prognosis improve over time?

Yes. Treatment advances — particularly immunotherapy (nivolumab plus ipilimumab) and tumor treating fields (TTFields) — have meaningfully improved survival expectations since 2020. Additionally, patients with favorable prognostic profiles including epithelioid histology, early-stage diagnosis, and treatment at specialized centers consistently outperform population averages.[36][23]

What is BAP1 and how does it affect prognosis?

BAP1 is a tumor suppressor gene. Patients carrying inherited (germline) BAP1 mutations develop a molecularly distinct form of mesothelioma with dramatically better prognosis — median survival of 5 years compared to less than 1 year for population controls. These patients show enhanced sensitivity to platinum-based chemotherapy and are more likely to survive long-term.[3][31]

What is the PLECH score?

PLECH is the newest validated mesothelioma prognostic scoring system (2025), using five weighted variables: Platelet count, LDH, ECOG performance status, Chest pain, and non-epithelioid Histology. Scores range from 0 to 7, with scores below 3 (low risk) predicting 20.1 months median survival versus 12.3 months for scores of 3 or higher. It outperforms both the CALGB and EORTC scores in predicting 1-year overall survival.[4]

Does gender affect mesothelioma prognosis?

Women with mesothelioma demonstrate approximately 50% better survival than men, with a hazard ratio of 0.78 for death and 5-year survival of 13.4% versus 4.5%. This difference may reflect hormonal factors, different exposure patterns (secondary versus occupational exposure), higher rates of epithelioid histology in women, and potentially different disease biology.[9][45]

How does the neutrophil-to-lymphocyte ratio predict outcomes?

The NLR is a simple blood test ratio that serves as a powerful prognostic biomarker. An elevated NLR is associated with a significantly higher hazard ratio for death, with substantially reduced one-year survival rates. NLR can be monitored throughout treatment to track disease trajectory and treatment response.[11]

Does treatment at a specialized center improve prognosis?

Research demonstrates that treatment at high-volume mesothelioma centers is associated with shorter hospitalization, lower readmission rates (4.6% vs. 6.1%), and lower 90-day mortality (10.0% vs. 14.6%). NCI-designated cancer centers with dedicated mesothelioma programs provide access to clinical trials, multidisciplinary teams, and high surgical volumes that improve outcomes.[14][21]

Should mesothelioma patients get genetic testing for BAP1?

Clinical practice guidelines (2023, European Journal of Human Genetics) recommend genetic counseling and testing for patients with mesothelioma, particularly those diagnosed at younger ages, those with family history of mesothelioma or related cancers (uveal melanoma, renal cell carcinoma), and those with limited or no known asbestos exposure history. BAP1 status has implications for prognosis, treatment planning, and family member surveillance.[33][41]

Quick Statistics

  • 12–21 months median overall survival for treated pleural mesothelioma patients[2]
  • 5 years median survival for mesothelioma patients with germline BAP1 mutations versus less than 1 year for non-carriers[3]
  • 47% five-year survival rate among BAP1 mutation carriers compared to 6.7% in SEER population controls[3]
  • 39.2% five-year survival for patients diagnosed under age 50 versus 4.5% for those 75 and older[10]
  • 13.4% five-year survival for women versus 4.5% for men — women have 22% lower mortality risk[9]
  • 104 months median survival for peritoneal mesothelioma patients achieving complete cytoreduction (CC-0) with HIPEC[12]
  • 0.70 AUC achieved by the 2025 PLECH score for predicting 1-year overall survival, the most accurate mesothelioma prognostic model[4]
  • Elevated hazard ratio for death when neutrophil-to-lymphocyte ratio is high, with significantly reduced survival rates[11]
  • 10.0% vs. 14.6% 90-day mortality at high-volume versus lower-volume mesothelioma surgery centers[14]

Get Help

If you or a loved one has been diagnosed with mesothelioma, understanding your individual prognosis is a critical first step toward making informed treatment and legal decisions. Multiple prognostic factors can be assessed through routine medical evaluations to help guide your path forward.

Legal Resources:

Medical Information:

Quick Reference:

Legal Resources:

References

  1. ↑ 1.0 1.1 Mesothelioma Diagnosis Guide, Danziger & De Llano
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 Determinants of Survival in Malignant Pleural Mesothelioma: A SEER Study of 14,228 Patients, PLOS ONE, 2015
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 Mesothelioma Patients with Germline BAP1 Mutations Have 7-Fold Improved Long-Term Survival, National Cancer Institute EDRN
  4. ↑ 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 4.11 4.12 4.13 4.14 4.15 Prognostic Factors in Pleural Mesothelioma Patients Receiving First-Line Chemotherapy: Establishing the PLECH Baseline Risk Score, Oncology, 2025
  5. ↑ 5.0 5.1 5.2 5.3 5.4 5.5 5.6 5.7 Prognostic Factors in Patients with Pleural Mesothelioma: The EORTC Experience, Journal of Clinical Oncology, 1998
  6. ↑ Mesothelioma Compensation, Danziger & De Llano
  7. ↑ Epithelial Mesothelioma, MesotheliomaAttorney.com
  8. ↑ Sarcomatoid Mesothelioma Guide, MesotheliomaAttorney.com
  9. ↑ 9.0 9.1 9.2 9.3 Women with Malignant Pleural Mesothelioma Have a Threefold Better Survival Rate Than Men, Annals of Thoracic Surgery, 2014
  10. ↑ 10.0 10.1 10.2 10.3 10.4 10.5 Factors Influencing Malignant Mesothelioma Survival, BMC Cancer, 2018
  11. ↑ 11.0 11.1 11.2 11.3 Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Patients with Mesothelioma: A Meta-Analysis, Oncotarget, 2017
  12. ↑ 12.0 12.1 12.2 12.3 Heated Intraperitoneal Chemotherapy (HIPEC), Mesothelioma.net
  13. ↑ 13.0 13.1 13.2 13.3 13.4 13.5 13.6 13.7 13.8 A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma, Clinical Cancer Research, 2016
  14. ↑ 14.0 14.1 14.2 14.3 Facility Volume and Postoperative Outcomes for Malignant Pleural Mesothelioma, Annals of Thoracic Surgery, 2018
  15. ↑ 15.0 15.1 Malignant Mesothelioma, Danziger & De Llano
  16. ↑ Mesothelioma Treatment (PDQ) — Patient Version, National Cancer Institute
  17. ↑ 17.0 17.1 Stages of Mesothelioma, Mesothelioma Lawyer Center
  18. ↑ Peritoneal Mesothelioma Cancer, Mesothelioma Lawyer Center
  19. ↑ Mesothelioma Treatment Centers, Mesothelioma.net
  20. ↑ 20.0 20.1 Top-Rated Mesothelioma Lawyers, Danziger & De Llano
  21. ↑ 21.0 21.1 21.2 NCI-Designated Cancer Centers, National Cancer Institute
  22. ↑ 22.0 22.1 22.2 Validation of CALGB and EORTC Prognostic Scoring Systems, British Journal of Cancer, 2000
  23. ↑ 23.0 23.1 23.2 Mesothelioma Treatment Guide, Mesothelioma Lawyer Center
  24. ↑ 24.0 24.1 BTS Guideline for the Investigation and Management of Pleural Mesothelioma, British Thoracic Society, 2018
  25. ↑ 25.0 25.1 Value of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy to treat malignant peritoneal mesothelioma, Wang T, Li H, Ye B, Zhang D. American Journal of Translational Research 2021;13(9):10712–10720 (PMID 34650746) — multivariate analysis identified ECOG score as an independent prognostic factor (OR 3.91, p=0.017) alongside TNM stage and treatment modality
  26. ↑ 26.0 26.1 First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial, Baas P, Scherpereel A, et al. Lancet 2021 (PMID 33485464)
  27. ↑ Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743, Scherpereel A, Baas P, et al. Journal of Clinical Oncology 2026 (PMID 41734361) — 5-year OS 14% vs. 6%
  28. ↑ Advances in diagnosis and management of pleural mesothelioma: the Danish clinical guidelines, Panou V, Sørensen JB, Ravn J, Santoni-Rugiu E. European Clinical Respiratory Journal 2025;12(1):2580795 (PMID 41179988)
  29. ↑ 29.0 29.1 29.2 Mesothelioma Life Expectancy and Survival Rate, Mesothelioma.net
  30. ↑ 30.0 30.1 Pleural vs Peritoneal Mesothelioma Differences, Danziger & De Llano
  31. ↑ 31.0 31.1 Inherited Predisposition to Malignant Mesothelioma and Overall Survival Following Platinum Chemotherapy, Proceedings of the National Academy of Sciences, 2019
  32. ↑ 32.0 32.1 Medical and Surgical Care of Mesothelioma Patients and Their Relatives Carrying Germline BAP1 Mutations, Journal of Thoracic Oncology, 2022
  33. ↑ 33.0 33.1 33.2 Clinical Practice Guidelines for the Diagnosis and Surveillance of BAP1 Tumor Predisposition Syndrome, European Journal of Human Genetics, 2023
  34. ↑ Survival Rates for Pleural Mesothelioma, American Cancer Society
  35. ↑ Mesothelioma Treatment, Mesothelioma.net
  36. ↑ 36.0 36.1 FDA Approves Nivolumab and Ipilimumab for Unresectable Malignant Pleural Mesothelioma, U.S. Food and Drug Administration, 2020
  37. ↑ First-Line Nivolumab Plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (CheckMate 743), The Lancet, 2021
  38. ↑ Mesothelioma Clinical Trials, ClinicalTrials.gov
  39. ↑ Mesothelioma, Mesothelioma Lawyer Center
  40. ↑ 40.0 40.1 40.2 40.3 Characteristics of Long-Term Survivors with Peritoneal Mesothelioma, Annals of Surgical Oncology, 2025
  41. ↑ 41.0 41.1 41.2 Case Report: Mesothelioma and BAP1 Tumor Predisposition Syndrome, Frontiers in Oncology, 2022
  42. ↑ Pleural Mesothelioma, MesotheliomaAttorney.com
  43. ↑ What's Your Mesothelioma Case Worth?, Danziger & De Llano
  44. ↑ Mesothelioma Compensation Guide, MesotheliomaAttorney.com
  45. ↑ Study Shows Higher Mesothelioma Survival Rates in Women, Mesothelioma Lawyer Center
  46. ↑ Asbestos & Mesothelioma Lawyers, Danziger & De Llano
  47. ↑ Find Top Mesothelioma Attorneys, Mesothelioma Lawyer Center
Retrieved from "https://wikimesothelioma.com/w/index.php?title=Mesothelioma_Prognosis&oldid=3149"